Toxicity of bevacizumab in combination with chemotherapy in older patients Journal Article
| Authors: | Mohile, S. G.; Hardt, M.; Tew, W.; Owusu, C.; Klepin, H.; Gross, C.; Gajra, A.; Lichtman, S. M.; Feng, T.; Togawa, K.; Ramani, R.; Katheria, V.; Hansen, K.; Hurria, A. |
| Article Title: | Toxicity of bevacizumab in combination with chemotherapy in older patients |
| Abstract: | Background. Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy. Patients and Methods. We conducted a prospective study of patients aged ≥65 years, which evaluated the association between geriatric assessment (GA) metrics and chemotherapy toxicity. We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. Results. From a total of 207 patients, 27 (13%) received bevacizumab plus chemotherapy and 180 (87%) received chemotherapy alone. Groups were similar in sociodemographic and cancer characteristics. There were no baseline differences in GA domains except that patients with heart disease were less likely to receive bevacizumab (4% vs. 26%, p<.01). Seventyeight percent of patientswhohadbevacizumabhadgrade3-5 toxicity compared to only 57% who received chemotherapy alone (p =.06). Patients receiving bevacizumab were more likely to develop grade 3 hypertension than those who receivedchemotherapyalone(15%vs.2%, p<.01). In multivariable analysis, factors associated with grade 3 or more toxicity included: bevacizumab (OR: 2.86, p =.04), CRC (OR: 2.54, p<.01), and baseline anemia (OR: 2.58, p=.03). Conclusion. Heart diseasewasmorecommonin thosewhodid not receive bevacizumab. Older patients who receive bevacizumab with chemotherapy have a higher odds of developing a grade 3-5 toxicity compared with those who receive chemotherapy alone. © AlphaMed Press 2013. |
| Keywords: | bevacizumab; chemotherapy; drug toxicity; health services for the aged; geriatric assessment |
| Journal Title: | The Oncologist |
| Volume: | 18 |
| Issue: | 4 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2013-01-01 |
| Start Page: | 408 |
| End Page: | 414 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2012-0351 |
| PROVIDER: | scopus |
| PMCID: | PMC3639527 |
| PUBMED: | 23576485 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 June 2013" - "CODEN: OCOLF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work